Coloplast A/S
CSE:COLO B
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| DK |
|
Coloplast A/S
CSE:COLO B
|
110.7B DKK |
Loading...
|
|
| JP |
|
Hoya Corp
TSE:7741
|
9.6T JPY |
Loading...
|
|
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
59.5B USD |
Loading...
|
|
| CH |
|
Alcon AG
SIX:ALC
|
30.3B CHF |
Loading...
|
|
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
14.2B USD |
Loading...
|
|
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.6B GBP |
Loading...
|
|
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
6B USD |
Loading...
|
|
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
41.5B CNY |
Loading...
|
|
| CH |
|
Ypsomed Holding AG
SIX:YPSN
|
4.1B CHF |
Loading...
|
|
| US |
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
4.8B USD |
Loading...
|
|
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
6.9T KRW |
Loading...
|
Market Distribution
| Min | -2 199.8% |
| 30th Percentile | 26.7% |
| Median | 45.7% |
| 70th Percentile | 65.9% |
| Max | 1 637.7% |
Other Profitability Ratios
Coloplast A/S
Glance View
Coloplast A/S, headquartered in Humlebæk, Denmark, has a storied history that dates back to 1954 when a nurse, Elise Sørensen, identified a crucial need in the healthcare sector. Her sister had undergone ostomy surgery, and the lack of appropriate post-operative care products inspired Sørensen to design the world’s first adhesive ostomy bag. This innovation laid the groundwork for Coloplast's trajectory in the healthcare industry. Today, the company has expanded its focus to include ostomy care, continence care, wound and skin care, and interventional urology. With a commitment to improving patients' quality of life, Coloplast has become a leader in designing and manufacturing products that not only highlight practicality but also embody comfort and discretion. Coloplast generates revenue through a business model that emphasizes product innovation and direct engagement with healthcare providers and patients. The company invests significantly in research and development to improve and widen its product offerings continuously. It operates globally, distributing its products directly and via partnerships with hospitals, clinics, and healthcare professionals. By maintaining an attentive approach to user experience and incorporating customer feedback into its development processes, Coloplast ensures its portfolio aligns with the actual needs of its users. This user-centered strategy not only enhances customer loyalty but also fortifies the company’s market position, driving its financial success.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Coloplast A/S is 67.9%, which is above its 3-year median of 67.4%.
Over the last 3 years, Coloplast A/S’s Gross Margin has decreased from 68.7% to 67.9%. During this period, it reached a low of 66.6% on Sep 30, 2023 and a high of 68.7% on Dec 31, 2022.